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Abstract. The objective of our study was to compare the effects of two remifentanil dosing regimens, used during 
induction-delivery period of cesarean section, and of remifentanil-free control on maternal intubating conditions and 
hemodynamic response to endotracheal intubation as well as on neonatal outcome. Seventy seven ASA physical status 
III women with singleton term pregnancy, who were scheduled for elective cesarean section in general anesthesia 
and have given written informed consent, were enrolled in this prospective, randomized controlled study and divided 
in three groups: A  31 patient received 1 µg/kg remifentanil bolus before the induction of anesthesia, followed by 
0.15 µg/kg/min remifentanil infusion that was stopped after the skin incision; B  27 patients received only 1 µg/kg 
remifentanil bolus; C  19 patients did not receive remifentanil until the delivery of the baby. Intubating conditions 
were qualified as excellent, good or poor. Group A had significantly higher number of patients with excellent 
intubating conditions (p = 0.011); majority of patients with good intubating conditions were in group C (p = 0.017). 
Systolic, diastolic, main arterial pressure and heart rate raised significantly in group C compared to A and B 
(p < 0.001). Neonatal outcome did not differ between groups – all neonates were vital with first minute Apgar scores 
≥ 8. In conclusion, our dosing regimen of remifentanil 1µg/kg bolus given immediately before the induction 
followed by 0.15 µg/kg/min interrupted after skin incision provided the best compromise between the 
achievement of excellent intubating conditions, attenuation of maternal hemodynamic stress response to 
endotracheal intubation and avoidance of neonatal respiratory depression. 




The time interval from induction to anesthesia to the de-
livery of the baby (induction-delivery, I-D interval) during 
caesarean section performed under general anesthesia 
(GA) represents very vulnerable period concerning both 
maternal and fetal/neonatal wellbeing. All medications 
that the mother receives (except muscle relaxants) will 
cross uteroplacental membrane and affect the fetus di-
rectly (hearth and respiratory rate, muscle tone) and indi-
rectly (by influencing maternal hemodynamics, uteropla-
cental perfusion, uterine tone) [13]. This is the reason 
why the doses of anesthetics are traditionally reduced as 
much as possible, which could lead to light anesthesia 
with increased risk of maternal intraoperative awareness 
(reported incidence of 0.2-0.9%) [4, 5] and exaggerated 
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neuroendocrine stress response to laryngoscopy, endotra-
cheal intubation and surgical stimuli. Mechanical stimula-
tion of pharyngeal and laryngeal proprioceptors during 
direct laryngoscopy, endotracheal intubation and cuff 
inflation activates hypothalamo-pituitary-adrenal axis, 
with subsequent increase in hearth rate (up to 20%), blood 
pressure (4050%), capillary wedge, intracranial and in-
traocular pressure, possibly leading to severe cardio- and 
cerebrovascular complications [69]. Increasing number 
of vulnerable patients in obstetrics population nowadays 
makes this problem more and more serious.  We can ex-
pect much more parturients with high-risk pregnancies, 
advanced age, morbid obesity and complex comorbidities 
and, consequently, much more need for some drug that 
could help us blunting the unwanted effects of endotra-
cheal intubation [9, 10].     
Among different pharmacological options used to 
attenuate hemodynamic response to endotracheal intu-
bation and surgical incision (direct vasodilatators, -
blockers, calcium channel blockers, 2 agonists, anti-
convulsant drugs such as gabapentin, magnesium, local 
anesthetics) opioids are still the most extensively used 
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[11, 12]. It seems that remifentanil, ultra-short acting 
synthetic opioid, due to its specific pharmacokinetics, 
could be the appropriate drug to use during I-D interval, 
where a brief but intense analgesia without prolonged 
effect is desirable [1318]. 
Remifentanil has a rapid onset of action (11.5 min), 
rapid redistribution and context sensitive half time 3-5 
min; its metabolism depends on nonspecific tissue and 
plasma esterases [19].  Remifentanil does cross the pla-
centa, but, unlike other opioids, appears to be rapidly 
metabolized and redistributed in the fetus leaving  the 
smaller possibility of unwanted consequences (mainly 
neonatal respiratory depression, muscle rigidity, low 
Apgar and neurobehavioral scores) [1921].    
In the present study we investigated the effects of 
two remifentanil dosing regimens on intubating condi-
tions and maternal blood pressure and heart rate re-
sponse to the intubation in attempt to find the most ef-
fective remifentanil dose that would not adversely affect 
neonatal outcome. 
Material and Methods 
The study was approved by the local ethics committee. 
Seventy-seven ASA physical status I-II women with 
singleton term pregnancy, who were scheduled for elec-
tive caesarean section in general anesthesia and have 
given written informed consent, were enrolled in this 
prospective, randomized controlled study. Exclusion 
criteria were known cardiac, respiratory, neurologic, 
renal, endocrine, psychiatric disorders, history of drug 
or alcohol abuse, morbid obesity, preeclampsia, pre-
dicted difficult airway management (Mallampati score 
> 2a), active labor, known fetal congenital abnormalities 
or signs of fetal compromise. All patients refused re-
gional anesthesia, or had absolute/relative medical con-
traindications to regional anesthesia.  
In the operating room patients were placed supine 
with left uterine displacement, standard monitoring 
(noninvasive blood pressure, electrocardiography, pulse 
oximetry, capnography – using  bedside monitor, model 
BSM-2301k, Nihon Kohden Corporation, Tokyo, Japan 
and bispectral index – BIS electroencephalogram, using 
BIS-Vista monitoring system Norwood, Massachusetts, 
USA) was initiated and two intravenous lines estab-
lished, one for remifentanil infusion (using Perfusor fm 
B/Brown , Melsungen AG, Germany), the other for the 
administration of other medications and fluids.  
Patients were randomly allocated (using envelope 
method) to one of the following groups:  
1. group (A)  31 patient received 1 µg/kg remifen-
tanil bolus, given over 30 s, before the induction of an-
esthesia, followed by 0.15 µg/kg/min remifentanil infu-
sion that was stopped after the skin incision. 
2. group (B)  27 patients received 1µg/kg remifen-
tanil bolus, given over 30 s, just before the induction of 
anesthesia 
3. control group (C)  19 patients did not receive 
remifentanil until the delivery  
After 3 minutes of preoxygenation through a face-
mask and remifentanil administration in A and B group, 
anesthesia was induced with thiopentone, starting with 
3 mg/kg over 20 s, followed by additional boluses (if 
needed) of 25 mg until adequate dept of anesthesia has 
been reached (BIS values under 60, but not below 40); 
succinylcholine 1.5 mg/kg was administered and after 
60 s endotracheal intubation was performed by the anes-
thetist blinded to group assignment, who also estimated 
and graded intubating conditions as excellent, good or 
poor (Table 1). The intubating score was evaluated ac-
cording to the consensus conference on Good Clinical 
Research Practice in Pharmacodynamic Studies of Neu-
romuscular Blocking Agents [22]. Anesthesia was main-
tained with 11.5% end-tidal sevoflurane and 50% ni-
trous oxide in oxygen. Further muscle relaxation has been 
provided with rocuronium 0.6 mg/kg. The lungs were 
mechanically ventilated to maintain end-tidal PCO2 of 
2832 mmHg, with fresh gas flow of 6 l/min. 
Beginning from the induction of anesthesia until de-
livery SAP, DAP, MAP (systolic, diastolic, main arterial 
pressure respectively) and HR (heart rate), were meas-
ured and recorded at 2 minutes interval. We specially 
Table 1 Scoring conditions for endotracheal intubation 
 Intubating conditions 




 excellent good poor 
Laryngoscop    
Jaw relaxation relaxed not fully poor 
Resistance to laryngoscope  none slight active 
Vocal cords    
Position  abducted intermediate closed 
Movements none moving closing 
Reaction to tube insertion and cuff inflation    
Limb movements                       none slight vigorous 
Cough none slight sustained (>10s) 
Conditions: excellent  – if all the answers are ’excellent’ 
 good  –  if the answers are ’excellent’ or ’good’  
 poor –   if one or more answers are ’bad’ 
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recorded values measured after induction to anesthesia 
(T1) and 30 s after endotracheal intubation (T2). 
After delivery, pediatrician blinded to group assign-
ment assessed the neonate and recorded the time to sus-
tained respiration, Apgar score at 1
st
  and 5
th
  minute and 
resuscitative measures (if required), that might have in-
cluded the use of tactile stimulation, beg-mask ventilation, 
endotracheal intubation or naloxone administration.  
Statistical analyses 
Statistical analysis was performed using SSPS statistic 
package, version 13. Normal distribution was evaluated 
with Kolmogorov-Smirnov test.  Analysis of variance 
(ANOVA) was used for parameters comparison be-
tween three groups, with subsequent post hoc analysis. 
In cases of irregular data distribution Kruskal-Wallis 
test was utilized, with subsequent post hoc analysis with 
Mann-Whitney U test. The Chi-square test was used to 
verify the relation between categorical variables. The 
statistic hypothesis was tested on the significance level 
for risk of α=0.05; the difference between samples was 
considered significant if p was < 0.05. 
Results 
Seventy seven ASA status I-II parturients were included 
in this study. Patient’s characteristics and surgical de-
tails are summarized in Table 2; no differences between 
groups have been observed. 
Hemodynamic variables measured after the induc-
tion to anesthesia did not show statistical difference 
between groups (Table 3). After the intubation all he-
modynamic variables in group C have raised signifi-
cantly compared to groups A and B. The increase in 
variables was also greater in group B compared to A, 
but the difference did not reach statistical significance 
(Table 3) 
The intubation conditions were excellent in 61 partu-
rient (79.2%), good in 15 (19.5%) and poor in one par-
turient (1.3%) (Graph 1). 
 
Graph 1 Intubation condition in our patients 
The intubation scores showed significant difference 
between groups (Table 4.).  
Table 2 Parturients characteristics and surgical details 
 Group 
F p 
A B C 
Age (years)  31.74 ± 4.46  31.22 ± 5.22  30.89 ± 1.04 0.202 0.818 
Gestation weeks  38.94 ± 0.72  39.04 ± 1.09  39.47 ± 0.90 2.162 0.122 
Weight (kg)  77.19 ± 13.27  82.37 ± 9.52  79.26 ± 11.84 2.216 0.918 
I-D interval (minutes)  11.22 ± 1.67  10.04 ± 1.81  10.37 ± 1.71 3.639 0.031 
U-D interval (seconds)  57.39 ± 18.93  58.00 ± 14.92  60.42 ± 22.25 0.165 0.848 
F-ANOVA 
Table 3 Hemodynamic variables after the induction to anesthesia (T1) and 30 s after the intubation (T2)    
 T1 F p 
Post 
Hoc A B C 
SAP1  110.03 ± 14.16  107.14 ± 12.59  116.89 ± 9.93 3.364 0.040 c 
SAP2  119.61 ± 13.95  121.89 ± 13.82  149.00 ± 14.50 29.302 <0.001 b, c 
DAP1  67.93 ± 10.99  71.28 ± 10.51  75.31 ± 14.60 2.313 0.106  
DAP2  75.71 ± 12.93  81.56 ± 10.65  98.21 ± 15.01 18.750 <0.001 b, c 
MAP1  85.80 ± 13.21  84.22 ± 13.01  91.05 ± 13.17 1.590 0.211  
MAP2  91.06 ± 12.60  96.70 ± 12.49  116.68 ± 14.76 23.292 <0.001 b, c 
HR1  97.06 ± 9.88  94.70 ± 9.96  103.15 ± 11.64 3.819 0.026 c 
HR2  100.68 ± 8.92  102.41 ± 11.02  109.68 ± 9.61 5.165 0.008 b, c  
F-ANOVA,  
a (A vs B), b (A vs C), c (B vs C) 
Abbreviations: SAP1 – systolic arterial pressure after the induction to anesthesia (mm Hg), SAP2 – systolic arterial pressure after 
the endotracheal intubation, DAP1 – diastolic arterial pressure after the induction to anesthesia  (mm Hg), DAP2 – diastolic 
arterial pressure after the endotracheal intubation (mm Hg), MAP1 – main arterial pressure after the induction to anesthesia (mm 
Hg), MAP2 – main arterial pressure after the endotracheal intubation (mm Hg),  HR1 – heart rate after the induction to anesthesia 
(beat per minute), HR2 – heart rate after the induction to anesthesia (beat per minute) 
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The greater percent of patients in group A had ex-
cellent sore (χ2 = 6.471; p = 0.011), while in group C 
42.1% of patients had good score (χ2 = 5.617; p = 0.017). 
Patients with good score in group A (two patients) had 
intermediate vocal cords position and moving. All 
patients with good score in group B (five patients) had 
intermediate vocal cord position and moving; two of 
them (7.4%) additionally  had slight cough. All patients 
with good score in group C had intermediate vocal cord 
position; four of them (21.2%) additionally had not fully 
relaxed jaw, one (5.3%) slight cough. Patient with poor 
intubation score had poor jaw relaxation, vocal cords in 
closed position and slight limb movements.    
Newborn characteristics are presented in Table 5, 
with no differences between groups in any of the esti-
mated variables. All neonates were vital (Apgar score 
≥ 8). The reanimation of neonates who did not start to 
breathe immediately consisted only of brief (12 
minutes) tactile stimulation or beg- mask ventilation. 
Discussion 
The number of studies reporting the use of remifentanil 
during I-D period of caesarean  section is increasing. The 
dosing regiments were different and so were maternal 
effects and neonatal outcomes [1315, 17, 18, 21, 23]. 
The suppression of exaggerated neuroendocrine response 
to endotracheal intubation and surgical stress was some-
times achieved at the expense of maternal hypotension or 
neonatal respiratory depression and lower first minute 
Apgar scores, so optimal remifentanil dosing regimen 
was yet to be determined. 
In presented article we compared the effects of two 
remifentanil dosing regimens with remifentanil-free 
control, (meaning traditionally performed anesthesia, 
with omission of opioids during I-D interval), hypothe-
sizing that remifentanil beneficial effects could justify 
its use. Group B received remifentanil bolus just before 
the induction to anesthesia. In group A remifentanil 
bolus was followed by infusion, meant to extent its an-
algesic effect to whole I-D period. The infusion was 
interrupted after skin incision; taking into account the 
average length of I-D period of caesarean section per-
formed at our Clinic (1011 min) and remifentanil con-
text sensitive half-time of 3 min, we believed this 
should leave enough time for remifentanil redistribution 
and metabolism in fetal circulation, thus diminishing the 
probability of neonatal respiratory depression.   
According to our results both remifentanil dosing 
regimens successfully blunted maternal hemodynamic 
response to endotracheal intubation. SAP, DAP, MAP 
and HR, measured 30 s after the intubation, were sig-
nificantly higher in group C than in groups A and B. 
The elevation of blood pressure after endotracheal intu-
bation was even less in group A than in group B, but at 
this point of the operation the difference did not reach 
statistical significance (this will be reached as soon as at 
skin incision,  but further analysis of maternal hemody-
namic was beyond the scope of this article).     
Intubating conditions (Table 5) in group A were also 
significantly better than in other groups. The excellent 
conditions were noted in 93.5% patients, compared to 
81.5% in group B and 52.6% in group C; the difference 
between groups B and C was significant as well. 
This finding did not come as a surprise, because it is 
known that remifentanil, used with propofol or thio-
pentone to facilitate endotracheal intubation, is an ac-
ceptable alternative to neuromuscular blocking drugs, 
since it may potentiate depression of the laryngeal re-
flexes [24]. Remifentanil boluses of 24 µg/kg (de-
pending on a study) with propofol 2 mg/kg or thiopen-
tone 5 mg/kg, provided satisfactory or excellent intu-
bating conditions [2528]. Remifentanil-hypnotics syn-
ergism could be particularly useful in cases in which 
muscle relaxants are contraindicated, e.g. myopathies or 
choline-esterase enzyme deficiency [28]. Alexander et 
Table 4 Intubation conditions   




A B C 
Poor 0.0 0.0 5.3 
13.276 0.010 Good 6.5   18.5 42.1 
excellent 93.5 81.5 52.6 
χ2 – chi square test 






A B C 
Ap
1
  8.81±0.55 8.81±0.48 8.63±0.49 2.969 0.227 
Ap
5
  9.03±0.31 8.93±0.26 8.89±0.32 2.972 0.226 
Breathing
* 




(% of newborns) tactile  stimulation 12.9 7.4 15.8 
 bag mask ventilation 9.7 11.1   10.5 
F-ANOVA  
χKW
2 Kruskal-Wallis test  
Abbreviation: Ap1 – Apgar score in 1st minute, Ap5  Apgar score in 5th minute 
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al. [29] reported successful use of 0.5 µg/kg remifen-
tanil followed by 0.25 µg/kg/min, together with thio-
pentone for endotracheal intubation in a parturient with 
suxamethonium apnea. 
Even when used with muscle relaxants, as in our 
study, remifentanil could be of great help in ameliorating 
intubating conditions, especially in cases where difficult 
intubation is anticipated. Due to physiologic changes of 
pregnancy, like airway edema, enlarged breasts, weight 
gain, change in Mallampati score, the risk of diffi-
cult/failed intubation is increased [1, 3]. The incidence of 
difficult and failed intubation in obstetric patients is 
16% and 0.130.6% respectively (0.130.3% in general 
surgical population); additionally, the tolerance to apnea 
is reduced as a consequence of reduced pulmonal func-
tional residual capacity and increased metabolic rate and 
oxygen consumption. This could lead to respiratory com-
plications, like coughing, bucking, laryngospasm and 
bronchospasm, hypercarbia and hypoxia [1, 7, 10], mak-
ing airway management problems one of the leading 
causes of anesthesia-related maternal mortality [2]. Ac-
cording to our results, the addition of remifentanil will 
help provide smooth endotracheal intubation, ameliorate 
intubation conditions and attenuate excessive hemody-
namic response. This effect could be particularly bene-
ficial in parturients with serious comorbidities, e.g. 
preeclampsia, but also in healthy obstetric population.  
Opposite to the data from the literature [15, 17, 18, 
21, 23], remifentanil regimens applied in our study did 
not affect neonatal outcome. First minute Apgar scores 
were ≥8 in all cases, without difference between groups. 
Majority of neonates (77.4% in group A, 81.4% in group 
B, 73.7% in group C) started breathing within few se-
conds after delivery. Resuscitative measures applied to 
the neonates with respiratory depression consisted of 
tactile stimulation and brief beg-mask ventilation with no 
significant difference between groups. There was no need 
for endotracheal intubation or for naloxone administra-
tion, and no muscular rigidity was observed. 
Conclusion 
Our dosing regimen of remifentanil 1µg/kg bolus 
given immediately before the induction followed by 
0.15 µg/kg/min interrupted after skin incision pro-
vided the best compromise between achievement of 
excellent intubating conditions, attenuation of mater-
nal blood pressure and heart rate  response to endotra-
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